GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)
< 1 minute read
Sep. 17, 2021
GSK620: an oral in vivo BD2 domain selective BET inhibitor
GSK620
BD2 domain selective BET inhibitor oral efficacy in 3 inflammation models from SBDD of a BD2-selective HTS hit Science, Mar. 19, 2020 GlaxoSmithKline, Stevenage, UK
Loading...
